Samantha Prout - Jul 10, 2023 Form 3 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Chief Accounting Officer
Signature
/s/ Christian Formica, Attorney-in-Fact
Stock symbol
FOLD
Transactions as of
Jul 10, 2023
Transactions value $
$0
Form type
3
Date filed
7/14/2023, 05:10 PM
Previous filing
Sep 8, 2021
Next filing
Aug 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FOLD Common Stock 137K Jul 10, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FOLD Stock Options (right to buy) Jul 10, 2023 Common Stock 2.94K $14.88 Direct F2
holding FOLD Stock Options (right to buy) Jul 10, 2023 Common Stock 2.38K $10.04 Direct F2
holding FOLD Stock Options (right to buy) Jul 10, 2023 Common Stock 7.57K $9.55 Direct F3
holding FOLD Stock Options (right to buy) Jul 10, 2023 Common Stock 13.8K $10.03 Direct F4
holding FOLD Stock Options (right to buy) Jul 10, 2023 Common Stock 17K $21.78 Direct F5
holding FOLD Stock Options (right to buy) Jul 10, 2023 Common Stock 56.7K $12.11 Direct F6
holding FOLD Stock Options (right to buy) Jul 10, 2023 Common Stock 55.2K $11.93 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The amount shown on this line represents Restricted Stock Units which will vest in varying quantities over the next four years, subject in each case to Ms. Prout's continued service with the Company through the applicable vesting dates.
F2 All of the options shown on this line are fully vested and exercisable.
F3 These options were granted on January 2, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 5,670 options are vested and exercisable and 1,896 remain unvested.
F4 These options were granted on April 15, 2020, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,878 options are vested and exercisable and 2,890 remain unvested.
F5 These options were granted on January 4, 2021, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 10,594 options are vested and exercisable and 6,369 remain unvested.
F6 These options were granted on January 14, 2022, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. Of the amount shown on this line, 21,263 options are vested and exercisable and 35,448 remain unvested.
F7 These options were granted on January 3, 2023, vesting and becoming exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter. All of the options shown on this line are unvested.